Similarly, the exclusion of bevacizumab (2) was expected, as it is known that EC does not use VEGF as an autocrine growth factor, and tumor angiogenesis is mainly driven by tumor produced VEGF [10]. The gene discussed is VEGFA; the disease is neoplasm.